R-PR Launches Taxotere In USA
Rhone-Poulenc Rorer launched its anticancer drug Taxotere (docetaxel) onto the US market on June 6 for the second-line treatment of patients with advanced breast cancer.
The drug was recently approved for treating locally-advanced or metastatic breast cancer which has progressed despite, or relapsed during, anthracycline-based therapy (Marketletter May 20). It is the second taxane drug to be launched in the USA after Bristol-Myers Squibb's Taxol (paclitaxel).
In a telephone briefing announcing the availability of the new drug, Howard Burris of the University of Texas Cancer Center said that while studies are now ongoing to compare Taxol and Taxotere, anecdotal and preclinical evidence has shown that R-PR's drug has pharmacokinetic characteristics which point to greater potency than Taxol, as well as more rapid detoxification from cells.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze